Neuroene Therapeutics is a cutting-edge brand focused on improving mitochondrial health to treat difficult-to-treat neurological diseases. With a team of experienced professionals and a groundbreaking mitochondrial modulator drug discovery platform, they aim to develop clinical candidates for diseases caused by underlying mitochondrial dysfunction. Their portfolio includes patents covering hundreds of analogs targeting various disease indications and their corresponding methods.

Co-founded by Dr. Sherine Chan, a mitochondrial biologist, and Dr. C.

James Chou, a medicinal chemist with a drug in clinical trials for Friedreich's Ataxia, Neuroene Therapeutics is driven by expertise. Supported by a team of esteemed advisors, they are dedicated to addressing medication-resistant diseases that affect millions of patients in the U. S.

By pushing the boundaries of scientific research, Neuroene Therapeutics is at the forefront of developing innovative therapies. Let Neuroene Therapeutics take you on a journey towards improved mitochondrial health and a brighter future